Factors circulating in the blood of type 2 diabetes mellitus patients affect osteoblast maturation – Description of a novel in vitro model
Creators
- 1. BG Trauma Center, Eberhard Karls Universität Tübingen, Schnarrenbergstr. 95, D-72076 Tübingen (Germany)
Description
Type 2 diabetes mellitus (T2DM) is one of the most frequent metabolic disorders in industrialized countries. Among other complications, T2DM patients have an increased fracture risk and delayed fracture healing. We have demonstrated that supraphysiological glucose and insulin levels inhibit primary human osteoblasts' maturation. We aimed at developing a more physiologically relevant in vitro model to analyze T2DM-mediated osteoblast changes. Therefore, SCP-1-immortalized pre-osteoblasts were differentiated with T2DM or control (non-obese and obese) sera. Between both control groups, no significant changes were observed. Proliferation was significantly increased (1.69-fold), while AP activity and matrix mineralization was significantly reduced in the T2DM group. Expression levels of osteogenic marker genes and transcription factors were altered, e.g. down-regulation of RUNX2 and SP-7 or up-regulation of STAT1, in the T2DM group. Active TGF-β levels were significantly increased (1.46-fold) in T2DM patients' sera. SCP-1 cells treated with these sera showed significantly increased TGF-β signaling (2.47-fold). Signaling inhibition effectively restored osteoblast maturation in the T2DM group. Summarizing our data, SCP-1 cells differentiated in the presence of T2DM patients' serum exhibit reduced osteoblast function. Thus, this model has a high physiological impact, as it can identify circulating factors in T2DM patients' blood that may affect bone function, e.g. TGF-β. - Highlights: • We present here a physiologically relevant in vitro model for diabetic osteopathy. • Blood of T2DM patients contains factors that affect osteoblasts' function. • The model developed here can be used to identify these factors, e.g. TGF-β. • Blocking TGF-β signaling partly rescues the osteoblasts' function in the T2DM group. • The model is useful to demonstrate the role of single factors in diabetic osteopathy
Availability note (English)
Available from http://dx.doi.org/10.1016/j.yexcr.2014.12.011Additional details
Identifiers
- DOI
- 10.1016/j.yexcr.2014.12.011;
- PII
- S0014-4827(14)00552-7;
Publishing Information
- Journal Title
- Experimental Cell Research
- Journal Volume
- 332
- Journal Issue
- 2
- Journal Page Range
- p. 247-258
- ISSN
- 0014-4827
- CODEN
- ECREAL
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47031865
- Subject category
- S60: APPLIED LIFE SCIENCES;
- Descriptors DEI
- ACTIN; BLOOD; COLLAGEN; CONNECTIVE TISSUE CELLS; DEVELOPED COUNTRIES; DIABETES MELLITUS; GLUCOSE; HEALING; IN VITRO; INSULIN; INTERFERON; PATIENTS; RADIOPROTECTIVE SUBSTANCES; SKELETON; TRANSCRIPTION; TRANSCRIPTION FACTORS; TRANSDUCERS
- Descriptors DEC
- ALDEHYDES; ANIMAL CELLS; BIOLOGICAL MATERIALS; BIOLOGICAL RECOVERY; BODY; BODY FLUIDS; CARBOHYDRATES; DISEASES; DRUGS; ENDOCRINE DISEASES; GROWTH FACTORS; HEXOSES; HORMONES; LYMPHOKINES; MATERIALS; METABOLIC DISEASES; MITOGENS; MONOSACCHARIDES; ORGANIC COMPOUNDS; ORGANS; PEPTIDE HORMONES; PROTEINS; RESPONSE MODIFYING FACTORS; SACCHARIDES; SCLEROPROTEINS; SOMATIC CELLS
Optional Information
- Copyright
- Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.